Skip to main content
. 2023 Jan 3;15(1):170. doi: 10.3390/pharmaceutics15010170

Table 2.

Main functions of the differentially expressed miRNAs in SMA with nusinersen therapy.

miRNA Log Fold Change p-Value Function PubMed Unique Identifier
miR-7-5p −3.22 1.47 × 10−8 Negative regulation of sprouting angiogenesis,
mRNA binding involved in posttranscriptional gene silencing
27431648,
31501273
miR-15a-5p −3.25 5.22 × 10−5 Enhances cell viability and inhibits apoptosis 32384924
miR-15b-5p −3.63 0.0003 Promotes neurogenesis and inhibits neural progenitor proliferation promotes proliferation, decreases apoptosis 20584895
32165184
miR-15b-3p −2.67 4.18 × 10−9
miR-126-5p −2.32 0.0005 Promotes angiogenesis and neurogenesis, master regulator of NMJ function,
Linked to neuronal loss, neurodegeneration and apoptosis in primary cultured spinal neurones
29773756
29773756
27748416
miR-127-3p −1.87 0.0001 Activate autophagy in the cortical neurons 33723216
miR-130a-3p −2.43 1.35 × 10−7 Regulate neurotransmitter synthesis 17855557
miR-146b-5p −1.81 8.84 × 10−5 Motor neuron loss caused by astrocyte-mediated pathology through NFkB signaling 28637335
miR-183-5p −1.76 1.04 × 10−5 Protein synthesis; axonal outgrowth 29160009, 24523674, 25055867, 26459109
miR-196b-5p −1.30 0.0022 Confines the rostrocaudal axis in the neural tube 20553899
miR-324-3p −1.20 9.28 × 10−5 Promotes neuronal differentiation and neurite outgrowth 23527072
miR-338-3p −1.52 5.54 × 10−8 Acts as a negative regulator of neuronal differentiation by suppressing apoptosis-associated tyrosine kinase and cytochrome oxidase complex IV 19020050
18684991
miR-378a-3p −1.59 0.0003 Promotes differentiation and inhibits proliferation of myoblasts in skeletal muscle development 27661135
miR-424-5p −1.88 8.65 × 10−6 Suppress microglia activation, regulation of cellular activities via interacting with specific lncRNA sponges 32065781

The filtering was informed by a comprehensive literature search using a constellation of single and combined key search terms in PubMed including ‘motor neuron development’, ‘neurodegeneration’, ‘spinal muscular atrophy’, ‘survival motor neuron protein’ and ‘nusinersen’. A negative log fold change indicates downregulation of miRNA in the follow-up phase of nusinersen therapy.